Cost minimization analysis (CMA) of capecitabine/cisplatin (XP) vs. 5-fu/cisplatin (FP) regimens in advanced gastric cancer (AGC) treatment in the romanian setting

Authors
Category Primary study
JournalValue in Health
Year 2011
This article has no abstract
Epistemonikos ID: 83aa7759b7401009d851a8684fe7b27d63512f19
First added on: Feb 04, 2025